Sodium Tungstate in Obesity

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of sodium tungstate versus placebo in patients with obesity (grade I and II).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Collaborators: Fundacio Clinic; Fundacio Clinic Barcelona

Criteria

Inclusion Criteria:

• BMI: 30-39.9 Kg/m2

• In case of male gender, 18 to 65 years old

• In case of female gender, diagnosis of menopause

• Body weight changes < 3 kg in the last 3 months

• In case of arterial hypertension or dyslipemia, no changes in dose in the last 2 months

Exclusion criteria:

• In case of female gender, absence of menopause

• Evidence of secondary causes of obesity

• Diabetes, type II

• Concomitant treatment with drugs affecting body weight

• Previous surgical intervention of obesity